VOR advances Phase III Telitacicept trials for myasthenia gravis, Sjögren’s
VOR says Telitacicept, a BAFF-APRIL inhibitor, is advancing in Phase III trials for myasthenia gravis and Sjögren’s, citing strong early enrollment and a differentiated B-cell targeting mechanism. Top-line MG data is anticipated in H1 2027.
Telitacicept, a BAFF-APRIL inhibitor, is advancing in phase III trials for myasthenia gravis and Sjögren's disease, with strong early enrollment and a differentiated mechanism targeting both upstream and downstream B-cell pathology. The company anticipates top-line MG data in H1 2027 and sees multi…